Table 3. Biological Activity of Human... | American Society of Hematology

Table 3.

Biological Activity of Human RvWF, LMW-rvWF, and PdvWF in vWF-deficient and Normal Dogs

Dog No.	Treatment	Dose		Half-Life		In Vivo Recovery		Maximum Increase in FVIII Activity	Time to Reach Max. FVIII Activity
		vWF:Ag (mg/kg)	RCoF (U/kg)	vWF:Ag (h)	RCoF (h)	vWF:Ag (%)	RCoF (%)	FVIII 2-Stage (%)	FVIII 2-Stage (h)
vWF-deficient
750	rvWF	46	35	22.1	4.7	64	78	173	24
751	rvWF	92	70	21.6	9.8	70	120	244	48
	pdvWF	10	63	7.7	NE^3-150	33	25	140	48
754	rvWF	97	75	NE^3-151	NE^3-151	59	110	226	48
1140	LMW-rvWF	45	6	9.0	NE^3-150	92	NE^3-150	195	48
Normal
H9510176	rvWF	45	35	14.5	6.5	33	96	NE	NE
	pdvWF	7.2	32	9.0	3.2	37	59	NE	NE

Dog No.	Treatment	Dose		Half-Life		In Vivo Recovery		Maximum Increase in FVIII Activity	Time to Reach Max. FVIII Activity
		vWF:Ag (mg/kg)	RCoF (U/kg)	vWF:Ag (h)	RCoF (h)	vWF:Ag (%)	RCoF (%)	FVIII 2-Stage (%)	FVIII 2-Stage (h)
vWF-deficient
750	rvWF	46	35	22.1	4.7	64	78	173	24
751	rvWF	92	70	21.6	9.8	70	120	244	48
	pdvWF	10	63	7.7	NE^3-150	33	25	140	48
754	rvWF	97	75	NE^3-151	NE^3-151	59	110	226	48
1140	LMW-rvWF	45	6	9.0	NE^3-150	92	NE^3-150	195	48
Normal
H9510176	rvWF	45	35	14.5	6.5	33	96	NE	NE
	pdvWF	7.2	32	9.0	3.2	37	59	NE	NE

Abbreviation: NE, not evaluated.

Not calculated because some values were below the limit of detection.

Treatment of dog no. 754 was on an emergency basis for a nose bleed; blood samples were therefore not taken at all time points.